Synergistic effects of ischemia and β-amyloid burden on cognitive decline in patients with subcortical vascular mild cognitive impairment

JAMA Psychiatry

Volumn 71, Issue 4, 2014, Pages 412-422

  Lee, Mi Ji ^a   Seo, Sang Won ^a   Na, Duk L ^a   Kim, Changsoo ^b   Park, Jae Hyun ^a   Kim, Geon Ha ^c   Kim, Chi Hun ^a   Noh, Young ^d   Cho, Hanna ^b   Kim, Hee Jin ^a   Yoon, Cindy W ^e   Ye, Byoung Seok ^a   Chin, Juhee ^a   Jeon, Seun ^f   Lee, Jong Min ^f   Choe, Yearn Seong ^a   Lee, Kyung Han ^a   Kim, Jae Seung ^g   Kim, Sung Tae ^a   Lee, Jae Hong ^g   Ewers, Michael ^h   Werring, David J ⁱ   Weiner, Michael W ^j,k   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d Gachon University College of Medicine   (South Korea)

^e Inha University School of Medicine   (South Korea)

^f Hanyang University   (South Korea)

^g University of Ulsan College of Medicine   (South Korea)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 11; PITTSBURGH COMPOUND B;

AGED; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; HUMAN; MAJOR CLINICAL STUDY; MENTAL DETERIORATION; MILD COGNITIVE IMPAIRMENT; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; SUBCORTICAL VASCULAR MILD COGNITIVE IMPAIRMENT; WHITE MATTER LESION;

AGED; AMYLOID BETA-PEPTIDES; BRAIN; BRAIN ISCHEMIA; CEREBRAL AMYLOID ANGIOPATHY; COMORBIDITY; CROSS-SECTIONAL STUDIES; DEMENTIA, VASCULAR; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; STATISTICS AS TOPIC;

EID: 84898629330     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.4506     Document Type: Article

References (47)

1. Frisoni GB, Galluzzi S, Bresciani L, Zanetti O, Geroldi C. Mild cognitive impairment with subcortical vascular features: clinical characteristics and outcome. J Neurol. 2002; 249 (10): 1423-1432.
2. O'Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol. 2003; 2 (2): 89-98.
3. Wentzel C, Rockwood K, MacKnight C, et al. Progression of impairment in patients with vascular cognitive impairment without dementia. Neurology. 2001; 57 (4): 714-716.
4. Seo SW, Cho SS, Park A, Chin J, Na DL. Subcortical vascular versus amnestic mild cognitive impairment: comparison of cerebral glucose metabolism. J Neuroimaging. 2009; 19 (3): 213-219.
5. Seo SW, Ahn J, Yoon U, et al. Cortical thinning in vascular mild cognitive impairment and vascular dementia of subcortical type. J Neuroimaging. 2010; 20 (1): 37-45
6. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 1997; 349 (9046): 151-154.
7. Roher AE, Tyas SL, Maarouf CL, et al. Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia. Alzheimers Dement. 2011; 7 (4): 436-444.
8. Shah NS, Vidal JS, Masaki K, et al.Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension. 2012; 59 (4): 780-786.
9. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004; 55 (3): 306-319.
10. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008; 29 (10): 1456-1465.
11. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008; 131 (pt 3): 665-680.
12. Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand 11C PIB uptake is increased in mild cognitive impairment. Neurology. 2007; 68 (19): 1603-1606.
13. Pike KE, Savage G, Villemagne VL, et al. β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007; 130 (pt 11): 2837-2844.
14. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging inmild cognitive impairment subtypes. Ann Neurol. 2009; 65 (5): 557-568.
15. Rowe CC, Ng S, Ackermann U, et al. Imaging β-amyloid burden in aging and dementia. Neurology. 2007; 68 (20): 1718-1725.
16. Marchant NL, Reed BR, DeCarli CS, et al. Cerebrovascular disease, β-amyloid, and cognition in aging. Neurobiol Aging. 2012; 33 (5): e25-e36. doi: 10.1016/j.neurobiolaging.2011.10.001.
17. Marchant NL, Reed BR, Sanossian N, et al. The aging brain and cognition: contribution of vascular injury and Aβ to mild cognitive dysfunction. JAMA Neurol. 2013; 70 (4): 488-495.
18. Lee JH, Kim SH, Kim GH, et al. Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. Neurology. 2011; 77 (1): 18-25.
19. Choi BR, Lee SR, Han JS, et al. Synergistic memory impairment through the interaction of chronic cerebral hypoperfusion and amyloid toxicity in a rat model. Stroke. 2011; 42 (9): 2595-2604.
20. Lee JS, ImDS, An YS, Hong JM, Gwag BJ, Joo IS. Chronic cerebral hypoperfusion in a mouse model of Alzheimer's disease: an additional contributing factor of cognitive impairment. Neurosci Lett. 2011; 489 (2): 84-88.
21. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56 (3): 303-308.
22. Ku HM, Kim JH, Kwon EJ, et al. A study on the reliability and validity of Seoul-Instrumental Activities of Daily Living (S-IADL). J Korean Neuropsychiatr Assoc. 2004; 43: 189-199.
23. Ahn HJ, Chin J, Park A, et al. Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci. 2010; 25 (7): 1071-1076.
24. Kim SH, Seo SW, Go SM, et al. Pyramidal and extrapyramidal scale (PEPS): a new scale for the assessment of motor impairment in vascular cognitive impairment associated with small vessel disease. Clin Neurol Neurosurg. 2011; 113 (3): 181-187.
25. Kang Y, Na DL, Hahn S. A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients [Korean]. J Korean Neurol Assoc. 1997; 15 (2): 300-308.
26. Seo SW, ImK, Lee JM, et al. Cortical thickness in single- versus multiple-domain amnestic mild cognitive impairment. Neuroimage. 2007; 36 (2): 289-297.
27. Kim H, Na DL. Normative data on the Korean version of the Boston Naming Test. J Clin Exp Neuropsychol. 1999; 21 (1): 127-133.
28. Kang Y, Na DL. Seoul Neuropsychological Screening Battery (SNSB). Incheon, Korea: Human Brain Research & Consulting Co; 2012.
29. Kang Y, Chin J, Na DL, Lee J, Park J. A normative study of the Korean version of Controlled OralWord Association Test (COWAT) in the elderly. Korean J Clin Psychol. 2000; 19: 385-392.
30. Lee J, Kang Y, Na DL. Efficiencies of Stroop interference indexes in healthy older adults and dementia patients. Korean J Clin Psychol. 2000; 19: 807-818.
31. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002; 15: 273-289.
32. Jeon S, Yoon U, Park J-S, et al. Fully automated pipeline for quantification and localization of white matter hyperintensity in brainmagnetic resonance image. Int J Imaging Syst Technol. 2011; 21: 193-200.
33. Greenberg SM, VernooijMW, Cordonnier C, et al; Microbleed Study Group. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009; 8 (2): 165-174.
34. Lo RY, JagustWJ; Alzheimer's Disease Neuroimaging Initiative. Vascular burden and Alzheimer disease pathologic progression. Neurology. 2012; 79 (13): 1349-1355.
35. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA. 2011; 305 (8): 822-823.
36. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991; 82 (4): 239-259.
37. Jack CR Jr, Lowe VJ, Weigand SD, et al; Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009; 132 (pt 5): 1355-1365.
38. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006; 129 (pt 11): 2856-2866.
39. Dierksen GA, Skehan ME, Khan MA, et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol. 2010; 68 (4): 545-548.
40. Mormino EC, Kluth JT, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated β-amyloid deposition in elderly subjects. Brain. 2009; 132 (pt 5): 1310-1323.
41. Hedden T, Mormino EC, Amariglio RE, et al. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci. 2012; 32 (46): 16233-16242.
42. Provenzano FA, Muraskin J, Tosto G, et al. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol. 2013; 70 (4): 455-461.
43. Freeman RQ, Giovannetti T, Lamar M, et al. Visuoconstructional problems in dementia: contribution of executive systems functions. Neuropsychology. 2000; 14 (3): 415-426.
44. Fang H, Zhang LF, Meng FT, Du X, Zhou JN. Acute hypoxia promotes the phosphorylation of tau via ERK pathway. Neurosci Lett. 2010; 474 (3): 173-177.
45. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001; 56 (4): 537-539.
46. Noh Y, Lee Y, Seo SW, et al. A new classification system for ischemia using a combination of deep and periventricular white matter hyperintensities [published online July 13, 2013]. J Stroke Cerebrovasc Dis. doi: 10.1016 /j.jstrokecerebrovasdis.2013.06.002.
47. Mathis CA, Kuller LH, Klunk WE, et al. In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann Neurol. 2012; 73 (6): 751-761.